After meeting with management, Jefferies analyst Eun Yang keeps a Buy rating on BioMarin with a $125 price target. With multiple clinical/regulatory catalysts in 2019, BioMarin is well positioned for upside, Yang tells investors in a research note. She believes the third-year durability data for valox in mid-2019 could potentially move the shares 20%.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.